Concepedia

Author

Francesco Merli

Istituti di Ricovero e Cura a Carattere ScientificoORCID

Also Known As

Andrea Ferrario, Arianna Di Rocco, Carmine Pinto, F Merli, F. Merli, F. Z. Merli, F.Z. Merli, FRANCESCO MERLI, Francesco Merli, Merli

331

Publications

9.8K

Citations

48

H-Index

105

Concepts

All Affiliations

Istituti di Ricovero e Cura a Carattere ScientificoUniversity of Modena and Reggio EmiliaAzienda Sanitaria Unità Locale di Reggio EmiliaAzienda Ospedaliera Citta' della Salute e della Scienza di TorinoAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
FM

About

Francesco Merli is an author at Istituti di Ricovero e Cura a Carattere Scientifico specializing in medicine, oncology, and pathology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

25

40

2.4K

2

Health Sciences

16

18

1K

3

Engineering

3

3

95

4

Public Health

3

3

198

5

Natural Sciences

1

1

31

Francesco Merli

×

111

Publications

9.1K

Citations

48

H-Index

YearCitations

Early Interim 2-[ <sup>18</sup> F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish Study

Andrea Gallamini, Martin Hutchings, Luigi Rigacci,

Journal of Clinical Oncology

2007

829

Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

Massimo Federico, Monica Bellei, Luigi Marcheselli,

Journal of Clinical Oncology

2009

736

Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study

Francesco Passamonti, Chiara Cattaneo, Luca Arcaini,

The Lancet Haematology

2020

551

Early Positron Emission Tomography Response–Adapted Treatment in Stage I and II Hodgkin Lymphoma: Final Results of the Randomized EORTC/LYSA/FIL H10 Trial

Marc André, T. Girinsky, Massimo Federico,

Journal of Clinical Oncology

2017

515

The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease.

Andrea Gallamini, Luigi Rigacci, Francesco Merli,

PubMed

2006

294

ABVD Compared With BEACOPP Compared With CEC for the Initial Treatment of Patients With Advanced Hodgkin's Lymphoma: Results From the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial

Massimo Federico, Stefano Luminari, Emilio Iannitto,

Journal of Clinical Oncology

2009

270

R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

Massimo Federico, Stefano Luminari, Alessandra Dondi,

Journal of Clinical Oncology

2013

261

Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

Viola Poeschel, Gerhard Held, Marita Ziepert,

The Lancet

2019

244

First-Line Treatment for Primary Testicular Diffuse Large B-Cell Lymphoma With Rituximab-CHOP, CNS Prophylaxis, and Contralateral Testis Irradiation: Final Results of an International Phase II Trial

Umberto Vitolo, Annalisa Chiappella, Andrés J.M. Ferreri,

Journal of Clinical Oncology

2011

233

Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients

Michel Meignan, Myriam Sasanelli, Olivier Casasnovas,

European Journal of Nuclear Medicine and Molecular Imaging

2014

185

Page 1